Loading
A phase 1/2 trial of Visugromab and Nivolumab in advanced solid tumours, run by CatalYm GmbH, active and no longer recruiting.
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) is a phase 1/2 interventional study registered as NCT04725474 by CatalYm GmbH, with 199 participants enrolled, started 2020-12-09 and due to reach its primary completion in 2028-04-30. Interventions recorded: visugromab (CTL-002) and nivolumab.
Shares Visugromab, CatalYm, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Immune checkpoint inhibitors and the tag pipeline.